Recent Updates
Recently added Catalysts
INDV Positive Sentiment Score: 65/100

Indivior to Announce Q2 and H1 2023 Results on July 27 th Slough, UK, and Richmond, VA

Key Takeaway: Indivior PLC has announced the release of its Q2 and H1 2023 financial results, scheduled for July 27th at 7:00 a.m. London time. The results will be accessible through the London Stock Exchange's Regulatory News Service and the company's website. A live webcast presentation led by CEO Mark Crossley will take place on the same day at 1:00 p.m. London time. Indivior is focused on developing treatments for substance use disorders and aims to make these chronic conditions more recognized and treated globally.

Market Sentiment Analysis

POSITIVE FACTORS

  • Indivior is actively engaging its investors with a detailed presentation scheduled for Q2 and H1 2023 results.
  • The company is expanding its pipeline to address various substance use disorders, reflecting a commitment to innovation.
  • Indivior aims to transform substance use disorders into recognized chronic diseases, showing a positive mission in healthcare.

Full Press Release Details

Indivior to Announce Q2 and H1 2023 Results on July
Slough, UK, and Richmond, VA, June 27, 2023 Indivior
PLC (LSE/NASDAQ: INDV) today announced that it will release its Q2 and H1 2023 results on July 27th at 7:00 a.m. London time (2:00 a.m. U.S. Eastern). The results will be available via the London
Stock Exchange s Regulatory News Service (RNS) and on the Investors section of the company s website at www.indivior.com.
Mark Crossley, Chief Executive Officer, and other members of Indivior s leadership team will host a presentation via live webcast at 1:00 p.m. London
time (8:00 a.m. U.S. Eastern) on July 27th.
Access to the Live Webcast Presentation
The webcast event and materials can be accessed on the Investors section of the company s website at www.indivior.com before the
Participants may access the presentation telephonically by registering with the following link:
(Registrants will have an option to be called back directly immediately prior to the call or be provided a call-in
# with a unique pin code following their registration)
A replay of the presentation will be available at www.indivior.com.
Indivior is a global pharmaceutical
company working to help change patients lives by developing medicines to treat substance use disorders (SUD) and serious mental illnesses. Our vision is that all patients around the world will have access to evidence-based treatment for the
chronic conditions and co-occurring disorders of SUD. Indivior is dedicated to transforming SUD from a global human crisis to a recognized and treated chronic disease. Building on its global portfolio of OUD
treatments, Indivior has a pipeline of product candidates designed to both expand on its heritage in this category and potentially address other chronic conditions and co-occurring disorders of SUD, including
alcohol use disorder and cannabis use disorder. Headquartered in the United States in Richmond, VA, Indivior employs more than 1,000 individuals globally and its portfolio of products is available in 39 countries worldwide. Visit
www.indivior.com to learn more. Connect with Indivior on LinkedIn by visiting www.linkedin.com/company/indivior.
Vice President, Investor Relations
Tel: 804-402-7123 or jason.thompson@indivior.com
Director, Investor Relations
Tel: 804-263-3978 or timothy.owens@indivior.com

Frequently Asked Questions

When will Indivior announce its Q2 and H1 2023 results?

Indivior will release its Q2 and H1 2023 results on July 27th at 7:00 a.m. London time.

How can I access Indivior's live webcast presentation?

The live webcast can be accessed on Indivior's Investors section of their website.

What is Indivior's mission?

Indivior aims to develop medicines for treating substance use disorders and mental illnesses.

Where is Indivior headquartered?

Indivior is headquartered in Richmond, VA, United States.

How many countries is Indivior's product portfolio available in?

Indivior's portfolio of products is available in 39 countries worldwide.

Last updated: Jun 27, 2023